Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experimentBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.37972.497234.44 (Published 12 February 2004) Cite this as: BMJ 2004;328:382
- Mark Sculpher, professor ()1,
- Stirling Bryan, professor2,
- Pat Fry, research fellow3,
- Patricia de Winter, research nurse3,
- Heather Payne, consultant in clinical oncology4,
- Mark Emberton, senior lecturer3
- 1Centre for Health Economics, University of York, Heslington, York YO10 5DD
- 2Health Economics Facility, Health Services Management Centre, University of Birmingham, Birmingham B15 2RT,
- 3Institute of Urology, Royal Free and University College Medical School, London W1P 7PN
- 4Meyerstein Institute of Oncology, Middlesex Hospital, London W1T 3AA
- Correspondence: M Sculpher
- Accepted 25 November 2003
Objective To establish which attributes of conservative treatments for prostate cancer are most important to men.
Design Discrete choice experiment.
Setting Two London hospitals.
Participants 129 men with non-metastatic prostate cancer, mean age 70 years; 69 of 118 (58%) with T stage 1 or 2 cancer at diagnosis.
Main outcome measures Men's preferences for, and trade-offs between, the attributes of diarrhoea, hot flushes, ability to maintain an erection, breast swelling or tenderness, physical energy, sex drive, life expectancy, and out of pocket expenses.
Results The men's responses to changes in attributes were all statistically significant. When asked to assume a starting life expectancy of five years, the men were willing to make trade-offs between life expectancy and side effects. On average, they were most willing to give up life expectancy to avoid limitations in physical energy (mean three months) and least willing to trade life expectancy to avoid hot flushes (mean 0.6 months to move from a moderate to mild level or from mild to none).
Conclusions Men with prostate cancer are willing to participate in a relatively complex exercise that weighs up the advantages and disadvantages of various conservative treatments for their condition. They were willing to trade off some life expectancy to be relieved of the burden of troublesome side effects such as limitations in physical energy.
Contributors MS and ME initiated the research and designed the study with SB, HP, and PF. PF undertook the interviews. SB and MS undertook the analyses, and MS produced the main drafts. MS and SB will act as guarantors for the paper. They accept full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish.
Funding This study was funded by an unrestricted grant from AstraZeneca
Competing interests MS, SB, and ME have been paid as consultants for AstraZeneca.
Ethical approval Approval was obtained from the local research ethics committee.
- Accepted 25 November 2003